Objective: To evaluate angiographic and clinical outcomes associated with open and closed dissection tunnel endoscopic vein harvesting (EVH) devices. Background: A previous PREVENT-IV (PRoject of Ex-vivo Vein graft ENgineering via Transfection IV) analysis reported that EVH for coronary artery bypass graft surgery was associated with worse outcomes than with traditional vein harvesting; however, outcomes by EVH device type were not available. Methods: Using data from the PREVENT-IV trial, we compared 1549 patients from 75 surgical sites who underwent EVH with open (n = 390) or closed (n = 1159) harvest tunnel devices. Outcomes included the incidence of vein graft failure at 12 to 18 months and a composite of death, myocardial infarction, and revascularization through 5 years.
studies have shown that endoscopic techniques reduce wound infections, bleeding, postoperative pain, and hospital stay durations. [2] [3] [4] [5] [6] [7] On the basis of these findings, a consensus statement endorsed the use of EVH over traditional harvesting, and by 2008, it was used in approximately 70% of patients undergoing CABG surgery in the United States. 1, 8 In an analysis of the PREVENT-IV (PRoject of Ex-vivo Vein graft ENgineering via Transfection IV) trial, we previously reported that EVH was associated with a higher rate of vein graft failure at 12 to 18 months and long-term mortality. 9 Similarly, a secondary analysis of the ROOBY trial reported lower vein graft patency and higher revascularization rates among patients who underwent EVH. 8 However, an analysis of Medicare patients in the Society of Thoracic Surgeons National Database reported no relationship between EVH and mortality, and among patients in the Northern New England Cardiovascular Disease Study, EVH was associated with lower mortality. 10, 11 One possible explanation for these discordant results could be the differential use and outcomes of specific EVH device types, although none of these studies were specifically designed to assess the comparative efficacy and safety of vein harvesting techniques.
There were 2 commercially available EVH devices used in the PREVENT-IV trial. 12 The closed tunnel system occludes the access site with a balloon and insufflates the dissection tunnel with up to 15 mm Hg pressure of carbon dioxide, whereas an open EVH system does not occlude the access site or pressurize the dissection tunnel. It has been hypothesized that a pressurized closed dissection tunnel could lead to intraluminal clot formation by slowing venous graft blood flow. 13 In addition, the closed tunnel system has a bullet-shaped dissector tip, which allows for more blunt dissection, whereas the open tunnel system has a spoon-shaped dissector tip. The lack of EVH device-specific information at the time of the original PREVENT-IV EVH analysis was a recognized limitation insofar as it precluded examining whether the observed vein graft failures were associated with specific EVH devices. 14 Accordingly, after collecting additional device-specific data, we sought to compare rates of vein graft failure and clinical outcomes in patients undergoing closed tunnel versus open tunnel EVH for CABG surgery.
METHODS

Patient Population
The design and results of the PREVENT-IV (ClinicalTrials.gov no. NCT00042081) trial have been previously described. 12, 15 Briefly, this was a phase III, double-blind, multicenter, placebo-controlled, randomized trial designed to assess the effects of edifoligide, an E2F transcription factor inhibitor, on ex vivo vein grafts in patients undergoing CABG surgery. A total of 3014 patients were enrolled at 2 or more vein grafts for atherosclerotic coronary artery disease. Major exclusion criteria included planned valvular surgery, prior cardiac surgery, nonatherosclerotic coronary artery disease, and comorbid illness expected to make 5-year survival unlikely. Each participating site received institutional review board approval, and all patients provided informed written consent.
EVH Devices and Identification
The primary analysis compared patients who underwent EVH with a closed tunnel system [Vasoview; MAQUET, Wayne, NJ (formerly Guidant Corporation, Natlick, MA)] with patients who underwent EVH with an open tunnel system [Clearglide; Sorin Group, Montvale, NJ (formerly Ethicon Cardiovations, Somerville, NJ, and Datascope Inc)]. EVH device information was obtained by contacting each PREVENT-IV study site. If a study hospital used both EVH systems, patient-specific harvesting device information was requested. Patients were excluded from this analysis if EVH device information was unavailable.
Outcome Measures
Angiographic endpoints were the per-graft and per-patient incidences of vein graft failure, defined as stenosis 75% or more of the vein graft diameter, and vein graft occlusion. All angiograms were interpreted in a central core laboratory blinded to harvesting technique (PERFUSE Angiographic Core Laboratory, Boston, MA). The angiographic outcomes analysis included EVH patients in the aforementioned angiographic cohort who completed the 12-to 18-month angiographic follow-up. Individuals who underwent angiography before 12 months for clinical reasons and met an angiographic endpoint were included in this analysis. Patients who died before angiographic follow-up were excluded. The primary clinical endpoint was the 5year composite outcome of death, myocardial infarction (MI), or revascularization. Other clinical endpoints were the individual components of composite outcomes.
Statistical Analysis
The distribution of baseline, perioperative surgical, and postoperative treatment characteristics was summarized with medians and 25th and 75th percentiles for continuous variables and with percentages for categorical variables. Group differences were assessed with the Wilcoxon rank-sum test (for continuous variables) and the χ 2 text (for categorical variables).
The incidence of vein graft failure was adjusted for predictors previously identified in the PREVENT-IV data set. 16 Vein graft failure was evaluated at both the patient and graft levels using mixed-effects logistic regression models. The patient-level graft failure model included study site as a random effect and the weight, duration of surgery, graft quality, target artery quality, and use of composite grafts as fixed effects. In the graft-level graft failure model, both patient and study site were modeled as random effects, whereas weight, duration of surgery, graft quality, target artery quality, and whether the graft was a composite or noncomposite graft were modeled as fixed effects.
Cumulative event rates and survival curves for the clinical outcomes were calculated by the Kaplan-Meier method, and outcome differences were assessed using a Cox proportional hazards model. Covariates associated with the primary clinical endpoint have been previously published. 9, 17 The variables included in the Cox proportional hazards model were age, sex, race, body mass index, hypertension, diabetes, heart failure, New York Heart Association class, recent MI, peripheral vascular disease, smoking, chronic lung disease, creatinine clearance, and poor target artery quality. A frailty model was used to determine whether survival times within study site were correlated and thus required adjustment for study site. 18 In a sensitivity analysis, we assessed whether the subset of patients who underwent EVH in this substudy (ie, device type was known) was similar to the group of all EVH patients enrolled in PREVENT-IV. We compared the clinical outcome of death, MI, or revascularization between (1) the subset of EVH patients used in this substudy and (2) patients who had open harvesting that were included in our original manuscript that compared EVH with open harvesting.
RESULTS
A total of 1753 patients in the PREVENT-IV trial underwent EVH, and 1549 patients (88.4%) from 75 of 107 study sites were included in this analysis. A total of 63 sites (n = 1153) used only a closed tunnel EVH system, 11 sites (n = 210) used only an open tunnel system, and 1 site (n = 215) used both systems. At 8 sites (n = 175), device-specific information could not be obtained and, therefore, those patients were excluded from this analysis ( Fig. 1) . From the open EVH group, 180 patients (46%) were from a single surgical site. The mean follow-up time was 5.1 years. The proportion of study patients at each study site undergoing EVH stratified by harvesting system is presented in Figure 2 . Baseline differences between the 1159 patients who underwent EVH with a closed system Vasoview (formerly Guidant Corporation) and the 390 patients who underwent EVH with an open system Clearglide (formerly Datascope Inc) were generally well balanced ( Table 1 ). The group of patients who underwent closed system harvesting had fewer current smokers, a lower prevalence of chronic lung disease, a lower median baseline heart rate, and a higher burden of underlying coronary artery disease. Perioperative surgical and postoperative treatment variables are presented in Table 2 . Patients with an open EVH system were more likely to undergo urgent surgery, undergo on-pump surgery, have a composite vein graft, have longer surgical times, and have longer lengths of stay. At 30 days, patients with an open EVH system were more likely to continue aspirin and thienopyridines but were less likely to continue statins.
Angiographic Outcomes
A total of 881 patients (56.9%) in this study had a follow-up angiogram within 18 months. The incidences of vein graft failure and graft occlusion are presented in Table 3 . No significant differences were observed in either the per-patient or per-graft unadjusted incidence of vein graft failure or occlusion, a finding that persisted after multivariable adjustment.
Clinical Outcomes
The 5-year Kaplan-Meier event rates for the composite outcome of death, MI, and revascularization were 23.9% for closed tunnel and 21.5% for open tunnel EVH ( Table 4 , Fig. 3 ). After multivariable adjustment, the 5-year risk of the primary composite outcome was similar among patients with open harvesting compared with closed harvesting (hazard ratio, 0.85; 95% confidence interval, 0.66-1.10; P = 0.221). Among secondary clinical outcomes, the 5-year Kaplan-Meier event rate for revascularization was numerically lower among patients who underwent open tunnel EVH (12.2% vs 16.4%); however, the relationship was not statistically significant after multivariable adjustment (hazard ratio, 0.73; 95% confidence interval, 0.53-1.03; P = 0.072).
In a sensitivity analysis, we compared the outcomes of patients who underwent EVH that were included in this analysis with the outcomes of patients who underwent open harvesting that were included in our original manuscript. 9 The 3-year risk of death, MI, or revascularization for patients who underwent EVH was higher than for those who underwent open harvesting and was similar to our previously published results (adjusted hazard ratio, 1.22; 95% confidence interval, 1.01-1.47; P = 0.04). harvested using a continuous linear skin incision that can extend from below the knee to its junction with the femoral vein just below the inguinal crease. 1 This technique potentially permits clear vein visualization, mobilization, and branch ligation but carries an increased risk of skin wound complications, hematomas, and longer hospital stays. [2] [3] [4] [5] 19, 20 In 1996, an EVH procedure was described as an alternative to standard vein procurement. 21 Multiple meta-analyses and small randomized trials subsequently reported advantages of EVH in terms of important short-term outcomes such as surgical site pain, cost, patient satisfaction, and harvest-site-wound complications. 2, [22] [23] [24] These analyses were neither powered nor designed to detect long-term differences in vein graft failure rates or major adverse cardiac outcomes. Observational analyses of the long-term safety of EVH are conflicting. Two studies have reported increased harm associated with EVH, including reduced vein graft patency and increased revascularization and death. 8, 9 However, studies by Williams et al 10 and Dacey et al 11 reported lower and no difference in long-term mortality, respectively. A limitation of all of the aforementioned analyses is a lack of information about EVH devices. EVH does not describe 1 homogeneous procedure. As previously mentioned, at the time of the PREVENT-IV trial, there were only 2 commercially available EVH devices in the United States: a closed tunnel system Vasoview (formerly Guidant Corporation) and an open tunnel system Clearglide (formerly Datascope Inc). A closed system uses a balloon to occlude the device entry site and the dissection tunnel is insufflated with carbon dioxide gas at 5 to 15 mm Hg pressure, whereas an open system does not use an occlusive balloon and the dissection tunnel is not pressurized. A small study by Brown and colleagues 13 reporting a lower unadjusted incidence of intraluminal venous clots in patients undergoing EVH with an open tunnel system led to the hypothesis that a pressured dissection tunnel can slow blood flow within a venous graft and lead to increased intraluminal clot; however, the present analysis did not detect a difference in EVH device-specific angiographic or clinical outcomes to support this putative hypothesis. 13 The lack of an observed difference between open and closed tunnel harvesting systems suggests that the increased risks of vein graft failures and clinical events observed among EVH patients in a previous PREVENT-IV analysis were not device specific. 9 The hypothesis that EVH may have detrimental effects on vein grafts is supported by a prospective, small study using multiphoton imaging, immunofluorescence, and biochemical techniques that demonstrated increased endothelial damage and reduced viability in EVH vein grafts. 25 This finding, however, has not been supported by all histological studies. 26 Importantly, EVH techniques continue to evolve, and modern EVH techniques may be different from those used during PREVENT-IV.
Implications for Current Practice and Future Research
Endoscopic harvesting of saphenous vein grafts clearly has important advantages for short-term outcomes such as wound infections, bleeding, pain, and length of hospitalization. In the context of conflicting outcomes associated with EVH in observational studies, which all have important methodological limitations, the long-term safety of EVH remains unclear. Importantly, we support calls to rigorously evaluate the safety of EVH in angiographic and clinical outcomes in an adequately powered randomized trial. 3, 8, 9 Limitations This study has several limitations that merit consideration. First, this study did not record measures of operator volume, which may be an important determinant of intimal and deep-vessel harvesting-related injuries. 27 Second, there was no protocol requirement for preharvest use of heparin, which may reduce vein graft clot burden. 13 Third, although the multivariable analysis adjusted for variables known to be associated with vein graft failure, the patients included in this analysis were not randomized. Fourth, more than 40% of patients undergoing EVH with a Clearglide (formerly Datascope Inc) device were from 1 study site and no study center information was available in our data set. We attempted to reduce the potential study center bias by modeling study center as a random effect when assessing vein graft failure. Study center was found to be nonsignificant as a random effect in the frailty model (P = 0.96). Therefore, the Cox proportional hazards models used to assess clinical outcomes did not include the random effect for study center. Fifth, the site of vein graph harvesting (thigh vs calf) was not available in our data set. Finally, the 5-year vein graph patency rate in this study was lower than that in some reports but is consistent with other published patency rates. 8,28
CONCLUSIONS
In a large cohort of patients undergoing CABG surgery with EVH, no difference was detected in the incidence of vein graft failure or occlusion between patients undergoing open or closed system EVH. In addition, no difference was detected in the 5-year incidence of death, MI, or revascularization. This analysis suggests that the higher incidences of vein graft failures and clinical events observed among EVH patients in the PREVENT-IV population are not related to a specific EVH device or system.
